Cure Sanfilippo Foundation and the National MPS Society have agreed a combined $5.5 million strategic investment in Spruce Biosciences, which will go towards the Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (or MPS IIIB) Expanded Access Program (EAP).  Samir Gharib, President and Chief Financial Officer of Spruce Biosciences, commented: “This investment […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!